Monitra Healthcare has announced the grant of U.S. Patent No. 12,109,029 B2, titled Wireless Cardiac Monitoring Device and Method to Measure and Transmit Cardiac Physiological Signals. Issued by the United States Patent and Trademark Office on 8 October 2024, the patent represents a step forward in the company’s efforts to innovate cardiac care.
The patented device is a wireless, patch-based cardiac monitoring system designed to enhance patient compliance and diagnostic accuracy. The device incorporates technology that automatically detects its orientation on the patient and selects electrode pairs for optimal signal quality. This eliminates errors caused by improper placement and ensures the effective processing of bio-potential signals. The physiological data is transmitted wirelessly in real time to external systems for analysis.
Key features of the device include advanced orientation detection to adapt to its placement on the patient, dynamic electrode pairing for optimised signal transmission, and seamless wireless connectivity for efficient ECG data transfer. Its lightweight, wire-free design enables prolonged use, improving comfort and usability for patients.
“This patent underlines our commitment to delivering cutting-edge technology that empowers clinicians with more reliable and actionable cardiac data. By addressing these critical needs, this innovation represents a leap forward in cardiac monitoring,” said Ravi Bhogu, Inventor and Founder of Monitra Healthcare.
Rajesh Sehgal, Managing Partner of Equanimity VC, commented, “Monitra Health’s innovation in cardiac monitoring aligns perfectly with our vision of supporting transformative solutions with global impact out of India. This patent highlights the company’s leadership in addressing critical unmet needs in cardiovascular diagnostics.”
“The grant of this U.S. patent is a testament to Monitra Health’s technological ingenuity and commitment to global excellence. We are pleased to support the company as it scales this innovation to reach patients and clinicians worldwide,” said Dhiraj Rajendran, Partner, Kotak Alternate Asset Managers.
The technology is positioned to redefine ambulatory ECG monitoring, particularly for conditions such as atrial fibrillation, cardiac arrhythmias, and QT prolongation monitoring in clinical trials. With the global burden of cardiovascular diseases rising, Monitra Healthcare plans to commercialise the technology and expand its market presence in regions such as the U.S., U.K., and Australia. The innovation aligns with the company’s mission to combat heart disease and improve health outcomes through accessible and reliable solutions.